1
|
Baba H, Hosoya T, Ishida R, Tai K, Hatsuzawa S, Kondo Y, Kusuhara H, Kagechika H, Yasuda S. Anti-Inflammatory Effects of a Novel Nuclear Factor- κB Inhibitory Derivative Derived from Pyrazolo[3,4- d]Pyrimidine in Three Inflammation Models. J Pharmacol Exp Ther 2024; 388:788-797. [PMID: 38253385 DOI: 10.1124/jpet.123.001904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 11/27/2023] [Accepted: 12/13/2023] [Indexed: 01/24/2024] Open
Abstract
Nuclear factor-κB (NF-κB) plays a central role in inflammatory responses, and its physiologic functions are essential for cell survival and proliferation. Currently, drugs targeting NF-κB inhibition have not yet been applied in clinical practice. We investigated the physiologic effect of a novel NF-κB inhibitory compound, 1H-pyrazolo[3,4-d]pyrimidin-4-amine derivative (INH #1), on three inflammatory animal models. The pharmacokinetics were measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis. Acute hepatitis was induced by administrating lipopolysaccharide (LPS) and D-(+)-galactosamine hydrochloride followed by the analysis of survival time and inflammatory mediators. Collagen-induced arthritis (CIA) was induced by immunization with type II collagen (CII), and serum-transfer arthritis (STA) was caused by injecting K/BxN mice serum. Clinical and histologic scores were evaluated in both arthritis models. Immune cell subset analysis, CII-induced interferon-gamma (IFN-γ) production and proliferation, and measurement of anti-CII IgG antibodies were performed in the CIA model. In the acute hepatitis model, INH #1 suppressed tumor necrosis factor-α (TNF-α) production and prevented early death in a dose-dependent manner. INH #1 significantly attenuated arthritis scores and joint inflammation in both arthritis models. Additionally, in the CIA model, dendritic cells (DCs) in the regional lymph nodes were decreased in the treated mice and antigen-induced IFN-γ production and cell proliferation in splenocytes were inhibited, whereas the titers of anti-CII IgG antibodies were comparable regardless of the treatment. Here we revealed that INH #1 exerted anti-inflammatory effects in vivo via inhibition of inflammatory mediators and suppression of cellular immune responses. This compound could be a novel candidate for inhibition of NF-κB in certain inflammatory diseases. SIGNIFICANCE STATEMENT: A novel nuclear factor-κB (NF-κB) inhibitory compound, 1H-pyrazolo[3,4-d]pyrimidin-4-amine derivative (INH #1), which retains physiologically essential NF-κB bioactivity, suppressed inflammation in three different mouse models: the acute hepatitis model, the collagen-induced arthritis model, and the K/BxN serum-transfer arthritis model. These results suggest that this compound could be a novel and potent anti-inflammatory agent.
Collapse
Affiliation(s)
- Hiroyuki Baba
- Department of Rheumatology, Graduate School of Medical and Dental Sciences (H.B., T.H., S.Y.), Institute of Biomaterials and Bioengineering (R.I., S.H., H.Ka.), and School of Medicine, Graduate School of Medical and Dental Sciences (Y.K.), Tokyo Medical and Dental University, Tokyo, Japan; and Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (K.T., H.Ku.)
| | - Tadashi Hosoya
- Department of Rheumatology, Graduate School of Medical and Dental Sciences (H.B., T.H., S.Y.), Institute of Biomaterials and Bioengineering (R.I., S.H., H.Ka.), and School of Medicine, Graduate School of Medical and Dental Sciences (Y.K.), Tokyo Medical and Dental University, Tokyo, Japan; and Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (K.T., H.Ku.)
| | - Ryosuke Ishida
- Department of Rheumatology, Graduate School of Medical and Dental Sciences (H.B., T.H., S.Y.), Institute of Biomaterials and Bioengineering (R.I., S.H., H.Ka.), and School of Medicine, Graduate School of Medical and Dental Sciences (Y.K.), Tokyo Medical and Dental University, Tokyo, Japan; and Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (K.T., H.Ku.)
| | - Kenpei Tai
- Department of Rheumatology, Graduate School of Medical and Dental Sciences (H.B., T.H., S.Y.), Institute of Biomaterials and Bioengineering (R.I., S.H., H.Ka.), and School of Medicine, Graduate School of Medical and Dental Sciences (Y.K.), Tokyo Medical and Dental University, Tokyo, Japan; and Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (K.T., H.Ku.)
| | - Saki Hatsuzawa
- Department of Rheumatology, Graduate School of Medical and Dental Sciences (H.B., T.H., S.Y.), Institute of Biomaterials and Bioengineering (R.I., S.H., H.Ka.), and School of Medicine, Graduate School of Medical and Dental Sciences (Y.K.), Tokyo Medical and Dental University, Tokyo, Japan; and Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (K.T., H.Ku.)
| | - Yuma Kondo
- Department of Rheumatology, Graduate School of Medical and Dental Sciences (H.B., T.H., S.Y.), Institute of Biomaterials and Bioengineering (R.I., S.H., H.Ka.), and School of Medicine, Graduate School of Medical and Dental Sciences (Y.K.), Tokyo Medical and Dental University, Tokyo, Japan; and Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (K.T., H.Ku.)
| | - Hiroyuki Kusuhara
- Department of Rheumatology, Graduate School of Medical and Dental Sciences (H.B., T.H., S.Y.), Institute of Biomaterials and Bioengineering (R.I., S.H., H.Ka.), and School of Medicine, Graduate School of Medical and Dental Sciences (Y.K.), Tokyo Medical and Dental University, Tokyo, Japan; and Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (K.T., H.Ku.)
| | - Hiroyuki Kagechika
- Department of Rheumatology, Graduate School of Medical and Dental Sciences (H.B., T.H., S.Y.), Institute of Biomaterials and Bioengineering (R.I., S.H., H.Ka.), and School of Medicine, Graduate School of Medical and Dental Sciences (Y.K.), Tokyo Medical and Dental University, Tokyo, Japan; and Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (K.T., H.Ku.)
| | - Shinsuke Yasuda
- Department of Rheumatology, Graduate School of Medical and Dental Sciences (H.B., T.H., S.Y.), Institute of Biomaterials and Bioengineering (R.I., S.H., H.Ka.), and School of Medicine, Graduate School of Medical and Dental Sciences (Y.K.), Tokyo Medical and Dental University, Tokyo, Japan; and Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (K.T., H.Ku.)
| |
Collapse
|
2
|
Sun J, Wei J, Zhang Y, Li J, Li J, Yan J, Guo M, Han J, Qiao H. Plasma Exosomes Transfer miR-885-3p Targeting the AKT/NFκB Signaling Pathway to Improve the Sensitivity of Intravenous Glucocorticoid Therapy Against Graves Ophthalmopathy. Front Immunol 2022; 13:819680. [PMID: 35265076 PMCID: PMC8900193 DOI: 10.3389/fimmu.2022.819680] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Accepted: 01/20/2022] [Indexed: 12/13/2022] Open
Abstract
Graves ophthalmopathy (GO), a manifestation of Graves' disease, is an organ-specific autoimmune disease. Intravenous glucocorticoid therapy (ivGCs) is the first-line treatment for moderate-to-severe and active GO. However, ivGCs is only effective in 70%-80% of GO patients. Insensitive patients who choose 12-week ivGCs not only were delayed in treatment but also took the risk of adverse reactions of glucocorticoids. At present, there is still a lack of effective indicators to predict the therapeutic effect of ivGCs. Therefore, the purpose of this study is to find biomarkers that can determine the sensitivity of ivGCs before the formulation of treatment, and to clarify the mechanism of its regulation of ivGCs sensitivity. This study first characterized the miRNA profiles of plasma exosomes by miRNA sequencing to identify miRNAs differentially expressed between GO patients with significant improvement (SI) and non-significant improvement (NSI) after ivGCs treatment. Subsequently, we analyzed the function of the predicted target genes of differential miRNAs. According to the function of the target genes, we screened 10 differentially expressed miRNAs. An expanded cohort verification showed that compared with NSI patients, mir-885-3p was upregulated and mir-4474-3p and mir-615-3p were downregulated in the exosomes of SI patients. Based on statistical difference and miRNA function, mir-885-3p was selected for follow-up study. The in vitro functional analysis of exosomes mir-885-3p showed that exosomes from SI patients (SI-exo) could transfer mir-885-3p to orbital fibroblasts (OFs), upregulate the GRE luciferase reporter gene plasmid activity and the level of glucocorticoid receptor (GR), downregulate the level of inflammatory factors, and improve the glucocorticoid sensitivity of OFs. Moreover, these effects can be inhibited by the corresponding miR inhibitor. In addition, we found that high levels of mir-885-3p could inhibit the AKT/NFκB signaling pathway, upregulate the GRE plasmid activity and GR level, and downregulate the level of inflammatory factors of OFs. Moreover, the improvement of glucocorticoid sensitivity by mir-885-3p transmitted by SI-exo can also be inhibited by the AKT/NFκB agonist. Finally, through the in vivo experiment of the GO mouse model, we further determined the relationship between exosomes' mir-885-3p sequence, AKT/NFκB signaling pathway, and glucocorticoid sensitivity. As a conclusion, plasma exosomes deliver mir-885-3p and inhibit the AKT/NFκB signaling pathway to improve the glucocorticoid sensitivity of OFs. Exosome mir-885-3p can be used as a biomarker to determine the sensitivity of ivGCs in GO patients.
Collapse
Affiliation(s)
- Jingxue Sun
- Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Jiaxing Wei
- Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Yaguang Zhang
- Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Jingjing Li
- Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Jian Li
- Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Jiazhuo Yan
- Department of Gynecological Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, China
| | - Min Guo
- Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Jun Han
- Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Hong Qiao
- Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| |
Collapse
|
3
|
Hu P, Dong ZS, Zheng S, Guan X, Zhang L, Li L, Liu Z. The effects of miR-26b-5p on fibroblast-like synovial cells in rheumatoid arthritis (RA-FLS) via targeting EZH2. Tissue Cell 2021; 72:101591. [PMID: 34325277 DOI: 10.1016/j.tice.2021.101591] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 06/17/2021] [Accepted: 07/07/2021] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To study the possible effects of miR-26b-5p on fibroblast-like synovial cells in rheumatoid arthritis (RA-FLS) through targeting enhancer of zeste homolog 2 (EZH2). METHODS Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect miR-26b-5p and EZH2 expressions in synovial tissues of RA patients and healthy controls. Dual luciferase reporter assay was adopted to verify the targeting relationship between miR-26b-5p and EZH2. RA-FLS was divided into Blank, mimics NC, mimics, NC siRNA, EZH2 siRNA and inhibitors + EZH2 siRNA groups, followed by the assessment of proliferation, apoptosis, migration and invasion. The expression of genes and proteins in RA-FLS was tested by qRT-PCR and western blotting, respectively. RESULTS MiR-26b-5p expression was lower, while EZH2 expression was higher in synovial tissue of RA patients than healthy controls; and miR-26b-5p was negatively correlated with the EZH2 in synovial tissue of RA patients, which were both related with disease activities. MiR-26b-5p can target EZH2 in RA-FLS. In vitro, miR-26b-5p mimics down-regulated EZH2 expression in RA-FLS. Compared with EZH2 siRNA group, the miR-26b-5p expression in inhibitors + EZH2 siRNA group was reduced, but EZH2 expression was increased. EZH2 siRNA inhibited the proliferation, invasion and migration of RA-FLS, promoted cell apoptosis, and inhibited the expression of TNF-α, IL-1β, IL-6, IL-17, MMP-2, MMP-9, which were reversed by miR-26b-5p inhibitor. CONCLUSION MiR-26b-5p may affect the biological characteristics of RA-FLS via targeting EZH2, including proliferation, apoptosis, invasion and migration, as well as the secretion of cytokines, thus playing a potential therapeutic role in RA.
Collapse
Affiliation(s)
- Pei Hu
- Department of Ultrasound, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China
| | - Zheng-Sen Dong
- Department of Ultrasound, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China
| | - Shuang Zheng
- Institute of Clinical Medicine, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China
| | - Xin Guan
- Department of Ultrasound, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China
| | - Lei Zhang
- Institute of Clinical Medicine, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China
| | - Lin Li
- Department of Ultrasound, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China.
| | - Zhen Liu
- Department of Ultrasound, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China.
| |
Collapse
|